<DOC>
	<DOC>NCT02378480</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.</brief_summary>
	<brief_title>Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Patients, ages 18 years or older who have signed the informed consent Has a qualifying skin and skin structure infection Female patients must not be pregnant at the time of enrollment Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug Infections where the outcome is strongly influenced by factors other than protocoldefined treatment and procedures, that require antibacterial treatment for greater than 14 days Evidence of significant immunological disease Severe sepsis or septic shock Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid Has received an investigational drug within past 30 days Women who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>